Su papel en la salud y la enfermedad | 10 MAR 14

El microbioma humano

Conceptos de este floreciente campo científico. Se explora su papel potencial, cada vez más evidente, en el estado de la enfermedad específica.
Autor/a: Dres. Sahil Khanna, Pritish K. Tosh Mayo Clin Proc. n January 2014;89(1):107-114
INDICE:  1.  | 2. Referencias

1 . Bäckhed F , Fraser CM , Ringel Y , et al . Definición de un humano sano gut microbioma : conceptos actuales , direcciones futuras , y clínica aplicaciones . Cell Host Microbio . 2012 ; 12 ( 5 ) :611 -622 .
2. Walter J, Ley R. The human gut microbiome: ecology and recent evolutionary changes. Ann Rev Microbiol. 2011;65:411-429.
3. Ahn J, Yang L, Paster BJ, et al. Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison. PloS One. 2011;6(7):e22788.
4. Marchesi JR. Human distal gut microbiome. Environ Microbiol. 2011;13(12):3088-3102.
5. Flint HJ. The impact of nutrition on the human microbiome. Nutr Rev. 2012;70(suppl 1):S10-S13.
6. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222-227.
7. Martinez I, Lattimer JM, Hubach KL, et al. Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J. 2013;7(2):269-280.
8. Biagi E, Nylund L, Candela M, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PloS One. 2010;5(5):e10667.
9. Backhed F. Host responses to the human microbiome. Nutr Rev. 2012;70(suppl 1):S14-S17.
10. Kelly D, Mulder IE. Microbiome and immunological interactions. Nutr Rev. 2012;70(suppl 1):S18-S30.
11. Brandt LJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile Infection. AmJ Gastroenterol. 2013;108(2):177-185.
12. Andoh A, Tsujikawa T, Sasaki M, et  al. Faecal microbiota profile of Crohn’s disease determined by terminal restriction fragment length polymorphism analysis. Aliment Pharmacol Ther. 2009;29(1):75-82.
13. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121(6):2126-2132.
14. Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev. Microbiol. 2013;11(9):639-647.
15. Russell SL, Finlay BB. The impact of gut microbes in allergic diseases. Curr Opin Gastroenterol. 2012;28(6):563-569.
16. Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr Opin Rheumatol. 2013;25(4):488-795.
17. Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome: current knowledge, challenges, and future directions. Transl Res. 2012;160(4):246-257.
18. Gevers D, Pop M, Schloss PD, Huttenhower C. Bioinformatics for the Human Microbiome Project. PLoS Comput Biol. 2012;8(11):e1002779.
19. Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87(11):1106-1117.
20. Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired Clostridium difficile infection: a populationbased study. Am J Gastroenterol. 2012;107(1):89-95.
21. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.
22. Ohman L, Simren M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep. 2013;15(5):323.
23. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007; 133(1):24-33.
24. Jeffery IB, O’Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006.
25. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38(6):475-483.
26. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033-1049.
27. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
28. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859-904.
29. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and noninflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7.
30. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36(6):503-516.
31. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis. 2008;46(suppl 2):S67-S72.
32. Tosh PK, McDonald LC. Infection control in the multidrugresistant era: tending the human microbiome. Clin Infect Dis. 2012;54(5):707-713.
33. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070-11075.
34. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444(7122):1022-1023.
35. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI.
The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Science Transl Med. 2009;1(6):6ra14.
36. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-916, e917.
37. Forsythe P. Probiotics and lung diseases. Chest. 2011;139(4):901-908.

AbstractAlthough, at first glance, these discoveries may seem esoteric, the clinical implications
of the microbiome in human health and disease are becoming clear. As such, it will soon be important for
practicing clinicians to have an understanding of the basic concepts of the human microbiome and its
relation to human health and disease. In this Concise Review, we provide a brief introduction to clinicians
of the concepts underlying this burgeoning scientific field and briefly explore specific disease states for
which the potential role of the human microbiome is becoming increasingly evident, including Clostridium
difficile infection, inflammatory bowel disease, colonization with multidrug-resistant organisms, obesity,
allergic diseases, autoimmune diseases, and neuropsychiatric illnesses, and we also discuss current and
future roles of microbiome restorative therapies.
ª 2014 Mayo Foundation for Medical Education and Research n Mayo



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023